LMP-420 is a selective tumor necrosis factor-α ( TNF-α ) inhibitor. LMP-420 reduces the release of pro-inflammatory cytokines (e.g., IL-1β, IL-2 ), inducing the expression of anti-inflammatory cytokine IL-10 and anti-apoptotic molecules SOCS-1 and Mn-SOD. LMP-420 also downregulates chemokines (e.g., IP-10, MCP-1) to reduce immune cell infiltration. LMP-420 is promising for research of type 1 diabetes mellitus, inflammatory diseases (e.g., colitis), and HIV-Mycobacterium tuberculosis coinfection.
Products | Products > Disease Areas > Infection | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > TNF Receptor | Products > Signaling Pathways > Interleukin Related
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.